t(8;9)(q24;p13) ?/MYC
2013-10-01 Jean-Loup Huret   Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL)
Phenotype stem cell origin
There were 5 cases of ALL (L3-ALLs and CD10+ ALLs in 2 cases each), 11 cases of diffuse large B-cell lymphoma (DLBCL), 7 cases of unclassifiable B-cell lymphoma, one case of follicular lymphoma, and one case of diffuse mixed small and large cell lymphoma (Levine et al., 1989; Nacheva et al., 1993; Dunphy et al., 2003; DAchille et al., 2006; Bertrand et al., 2007; Le Gouill et al., 2007; Christie et al., 2008; Johnson et al., 2009; Subramaniyam et al., 2011).
Epidemiology
Twenty five cases are available. There were 12 male and 13 female patients, median age was 63 years (range 42-90 years). In a review of NHLs with a t(14;18)(q32;q21), the incidence of MYC translocations was 5%, and the incidence of t(8;9)(q24;p13) was 1% (Johansson et al., 1995).

Meta-analysis of survival in patients with t(8;9)(q24;p13).
Prognosis
Median survival was 4 months (see figure). However, patients with an ALL died at 1, 1, 1.5, and 1.5 months. Median survival of patients with NHL was 6 months, and 3 out of 19 NHL patients were still alive 5 years after diagnosis (16%).
Genes Involved and Proteins
Note
Breakpoints occurred close to MYC on chromosome 8 and close to: ZBTB5, ZCCHC7, and PAX5 on chromosome 9 (Bertrand et al., 2007; Le Gouill et al., 2007; Johnson et al., 2009).
- ZBTB5 is a POZ domain Krüppel-like zinc finger transcription repressor. ZBTB5 interacted with co-repressor-histone deacetylase complexes such as BCOR, NCOR1, and NCOR2 (SMRT), resulting in deacetylation of histones Ac-H3 and Ac-H4, and transcriptional repression of CDKN1A (p21) (Koh et al., 2009).
- ZCCHC7 is the equivalent of the yeast AIR1. In yeast, a number of unwanted RNA transcripts are first recognized by the nuclear exosome cofactor Trf4/5p-Air1/2p-Mtr4p polyadenylation (TRAMP) complex before subsequent nuclear-exosome-mediated degradation. TRAMP facilitates pre-mRNA splicing (Kong et al., 2013).
- PAX5 is a lineage-specific transcription factor; recognizes the concensus recognition sequence GNCCANTGAAGCGTGAC, where N is any nucleotide. Involved in B-cell differentiation. Entry of common lymphoid progenitors into the B cell lineage depends on E2A, EBF1, and PAX5; activates B-cell specific genes and represses genes involved in other lineage commitments. Activates the surface cell receptor CD19 and represses FLT3. PAX5 physically interacts with the RAG1/RAG2 complex, and removes the inhibitory signal of the lysine-9-methylated histone H3, and induces V-to-DJ rearrangements. Genes repressed by PAX5 expression in early B cells are restored in their function in mature B cells and plasma cells, and PAX5 repressed (Fuxa et al., 2004; Johnson et al., 2004; Zhang et al., 2006; Cobaleda et al., 2007).
- ZBTB5 is a POZ domain Krüppel-like zinc finger transcription repressor. ZBTB5 interacted with co-repressor-histone deacetylase complexes such as BCOR, NCOR1, and NCOR2 (SMRT), resulting in deacetylation of histones Ac-H3 and Ac-H4, and transcriptional repression of CDKN1A (p21) (Koh et al., 2009).
- ZCCHC7 is the equivalent of the yeast AIR1. In yeast, a number of unwanted RNA transcripts are first recognized by the nuclear exosome cofactor Trf4/5p-Air1/2p-Mtr4p polyadenylation (TRAMP) complex before subsequent nuclear-exosome-mediated degradation. TRAMP facilitates pre-mRNA splicing (Kong et al., 2013).
- PAX5 is a lineage-specific transcription factor; recognizes the concensus recognition sequence GNCCANTGAAGCGTGAC, where N is any nucleotide. Involved in B-cell differentiation. Entry of common lymphoid progenitors into the B cell lineage depends on E2A, EBF1, and PAX5; activates B-cell specific genes and represses genes involved in other lineage commitments. Activates the surface cell receptor CD19 and represses FLT3. PAX5 physically interacts with the RAG1/RAG2 complex, and removes the inhibitory signal of the lysine-9-methylated histone H3, and induces V-to-DJ rearrangements. Genes repressed by PAX5 expression in early B cells are restored in their function in mature B cells and plasma cells, and PAX5 repressed (Fuxa et al., 2004; Johnson et al., 2004; Zhang et al., 2006; Cobaleda et al., 2007).
Gene name
MYC v-myc myelocytomatosis viral oncogene homolog (avian)
Location
8q24.21
Protein description
DNA binding protein. Binds DNA as a heterodimer with MAX. Involved in various cellular processes including cell growth, proliferation, cell adhesion, apoptosis, angiogenesis, and stem cell behaviour modulation.
Result of the Chromosomal Anomaly
Expression localisation
There was abundant MYC expression in all the cases studied.
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 36835628 | 2023 | The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. | 330 |
| 30909496 | 2019 | MYC Oncogene Contributions to Release of Cell Cycle Brakes. | 243 |
| 33322239 | 2020 | The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. | 230 |
| 22464321 | 2012 | MYC on the path to cancer. | 229 |
| 26382145 | 2015 | MYC, Metabolism, and Cancer. | 223 |
| 40290126 | 2025 | Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. | 193 |
| 28505071 | 2017 | MYC-Master Regulator of the Cancer Epigenome and Transcriptome. | 192 |
| 37941901 | 2023 | MYC function and regulation in physiological perspective. | 191 |
| 34942444 | 2022 | Therapeutic targeting of "undruggable" MYC. | 159 |
| 31832515 | 2019 | Writing and erasing MYC ubiquitination and SUMOylation. | 159 |
| 34658888 | 2021 | Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy. | 158 |
| 35741402 | 2022 | MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging. | 156 |
| 28245597 | 2017 | MYC in Regulating Immunity: Metabolism and Beyond. | 142 |
| 25274755 | 2014 | Therapeutic strategies to inhibit MYC. | 138 |
| 36417849 | 2022 | MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. | 127 |
| 32071436 | 2020 | Target gene-independent functions of MYC oncoproteins. | 126 |
| 36734615 | 2023 | Demystifying the Druggability of the MYC Family of Oncogenes. | 122 |
| 33692331 | 2021 | Alternative approaches to target Myc for cancer treatment. | 121 |
| 34178666 | 2021 | Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy. | 120 |
| 37457123 | 2023 | Targeting MYC-driven lymphoma: lessons learned and future directions. | 116 |
| 8615760 | 1996 | Myc oncogenes: the enigmatic family. | 112 |
| 32160543 | 2020 | MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. | 105 |
| 33092025 | 2020 | MYC in Brain Development and Cancer. | 99 |
| 29527331 | 2018 | Targeting oncogenic Myc as a strategy for cancer treatment. | 97 |
| 38565249 | 2024 | A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies. | 84 |
| 21293188 | 2011 | Post-translational control of Myc function during differentiation. | 83 |
| 40311680 | 2025 | MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage. | 82 |
| 29173017 | 2020 | MYC leads the way. | 81 |
| 41970279 | 2026 | MYC and AP-1 oncogenes cooperatively bind enhancers to rewire transcription. | 80 |
| 24696454 | 2014 | Stress-induced cleavage of Myc promotes cancer cell survival. | 79 |
| 21113411 | 2010 | Myc, mondo, and metabolism. | 73 |
| 26697836 | 2015 | Deubiquitinating c-Myc: USP36 steps up in the nucleolus. | 71 |
| 29078288 | 2017 | PAF1 complex component Leo1 helps recruit Drosophila Myc to promoters. | 70 |
| 27756891 | 2016 | c-Myc deregulation induces mRNA capping enzyme dependency. | 69 |
| 32715994 | 2020 | Dissecting transcriptional amplification by MYC. | 68 |
| 31679823 | 2019 | Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. | 67 |
| 36351945 | 2022 | Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution. | 66 |
| 40372972 | 2025 | Targeting processive transcription for Myc-driven circuitry in medulloblastoma. | 66 |
| 25475704 | 2015 | Taming of the beast: shaping Myc-dependent amplification. | 65 |
| 41698889 | 2026 | Palmitic acid activates c-Myc via dual palmitoylation-dependent pathways to promote colon cancer. | 64 |
| 25640402 | 2015 | Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. | 64 |
| 24394940 | 2014 | c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. | 63 |
| 24567369 | 2014 | The myc 3' wnt-responsive element suppresses colonic tumorigenesis. | 62 |
| 31455158 | 2019 | Oncogenic MYC amplifies mitotic perturbations. | 61 |
| 35089787 | 2022 | Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor. | 60 |
| 31043611 | 2019 | Inhibition of MYC by the SMARCB1 tumor suppressor. | 56 |
| 28800127 | 2017 | Mnt modulates Myc-driven lymphomagenesis. | 55 |
| 27566402 | 2016 | MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation. | 55 |
| 20598117 | 2010 | Myc suppression of Nfkb2 accelerates lymphomagenesis. | 54 |
| 30158517 | 2018 | MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability. | 54 |
| 35048559 | 2022 | A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. | 51 |
| 31570506 | 2019 | ZFP281 Recruits MYC to Active Promoters in Regulating Transcriptional Initiation and Elongation. | 51 |
| 32482868 | 2020 | MYC protein stability is negatively regulated by BRD4. | 50 |
| 35296795 | 2022 | Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis. | 50 |
| 30911685 | 2019 | Myc-driven chromatin accessibility regulates Cdc45 assembly into CMG helicases. | 49 |
| 31638140 | 2020 | NSD3S stabilizes MYC through hindering its interaction with FBXW7. | 49 |
| 40365020 | 2025 | Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer's master regulator. | 48 |
| 24297863 | 2014 | BET bromodomain inhibition of MYC-amplified medulloblastoma. | 46 |
| 34233962 | 2021 | The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. | 43 |
| 23318434 | 2013 | Dual regulation of Myc by Abl. | 43 |
| 30453475 | 2018 | Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition. | 41 |
| 31611367 | 2019 | Heterogeneity of Myc expression in breast cancer exposes pharmacological vulnerabilities revealed through executable mechanistic modeling. | 40 |
| 35167621 | 2022 | Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature. | 39 |
| 26766587 | 2016 | The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity. | 38 |
| 35962189 | 2022 | Myc inhibition tips the immune balance to promote antitumor immunity. | 36 |
| 36018850 | 2022 | S146L in MYC is a context-dependent activating substitution in cancer development. | 36 |
| 40886822 | 2025 | Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. | 35 |
| 33791309 | 2021 | MYC Enhances Cholesterol Biosynthesis and Supports Cell Proliferation Through SQLE. | 34 |
| 35438057 | 2022 | Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF(Fbxl8). | 32 |
| 36844467 | 2023 | AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers. | 30 |
| 31932576 | 2020 | High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? | 28 |
| 38184753 | 2024 | Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential. | 26 |
| 26383167 | 2015 | The MYC-WDR5 Nexus and Cancer. | 24 |
| 24704206 | 2015 | Myc and cell cycle control. | 0 |
| 33524794 | 2021 | MYC as a target for cancer treatment. | 0 |
| 34019288 | 2021 | MYC Analysis in Cancer and Evolution. | 0 |
| 24006054 | 2013 | The Myc world within reach. | 0 |
| 39306615 | 2024 | MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation. | 0 |
| 3034933 | 1987 | Myc family of cellular oncogenes. | 0 |
| 37561633 | 2023 | A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis. | 0 |
| 1751543 | 1991 | c-myc oncoprotein function. | 0 |
| 24933113 | 2015 | Myc and its interactors take shape. | 0 |
| 11885563 | 2002 | The myc oncogene: MarvelouslY Complex. | 0 |
| 25553514 | 2015 | MYC-mediated synthetic lethality for treating tumors. | 0 |
| 10078200 | 1999 | Ras enhances Myc protein stability. | 0 |
| 39468222 | 2025 | Transcriptional regulation by MYC: an emerging new model. | 0 |
| 31068032 | 2019 | MYC modulators in cancer: a patent review. | 0 |
| 34019290 | 2021 | Analysis of Myc Chromatin Binding by Calibrated ChIP-Seq Approach. | 0 |
| 25564254 | 2015 | MYC-mediated synthetic lethality for treatment of hematological malignancies. | 0 |
| 34019283 | 2021 | An "-omycs" Toolbox to Work with MYC. | 0 |
| 32074595 | 2020 | The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma. | 0 |
| 10579912 | 1999 | Function of the c-Myc oncogenic transcription factor. | 0 |
| 17012843 | 2006 | Myc overexpression enhances apoptosis induced by small molecules. | 0 |
| 10378694 | 1999 | The role of c-myc in cellular growth control. | 0 |
| 23696362 | 2013 | Myc in stem cell behaviour: insights from Drosophila. | 0 |
| 41489490 | 2026 | Alternative Strategies of Reducing MYC Expression for the Treatment of Cancers. | 0 |
| 30300580 | 2018 | MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. | 0 |
| 12565816 | 2003 | Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. | 0 |
| 19806017 | 2009 | MYC, microRNAs and glutamine addiction in cancers. | 0 |
| 19887915 | 2009 | Myc's secret life without Max. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 17230227 | 2007 | Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. | Bertrand P et al |
| 18297523 | 2008 | C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? | Christie L et al |
| 17440452 | 2007 | Pax5: the guardian of B cell identity and function. | Cobaleda C et al |
| 17074591 | 2006 | Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. | D'Achille P et al |
| 12708908 | 2003 | Mature B-cell acute lymphoblastic leukemia with associated translocations (14;18)(q32;q21) and (8;9)(q24;p13). A Burkitt variant? | Dunphy CH et al |
| 15004008 | 2004 | Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. | Fuxa M et al |
| 7579360 | 1995 | Cytogenetic evolution patterns in non-Hodgkin's lymphoma. | Johansson B et al |
| 15258579 | 2004 | B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. | Johnson K et al |
| 19597184 | 2009 | Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. | Johnson NA et al |
| 19491398 | 2009 | A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. | Koh DI et al |
| 24097436 | 2014 | Cotranscriptional recruitment of yeast TRAMP complex to intronic sequences promotes optimal pre-mRNA splicing. | Kong KY et al |
| 18024371 | 2007 | The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. | Le Gouill S et al |
| 2506953 | 1989 | Four new recurring translocations in non-Hodgkin lymphoma. | Levine EG et al |
| 8324225 | 1993 | C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353). | Nacheva E et al |
| 21718139 | 2011 | De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13. | Subramaniyam S et al |
| 16680144 | 2006 | Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes. | Zhang Z et al |
Citation
Jean-Loup Huret
t(8;9)(q24;p13) ?/MYC
Atlas Genet Cytogenet Oncol Haematol. 2013-10-01
Online version: http://atlasgeneticsoncology.org/haematological/2141/t(8
